Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, PhD, discuss new data and studies in MDS and MPNs presented at ASH 2020.
Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD
Released: February 5, 2021

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:

  • 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
  • A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
  • 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
  • Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
  • Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.

Presenters:

Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

On-demand webcast from a satellite symposia at the 2021 Hematology meeting on diagnosis and management of aTTP, from Clinical Care Options (CCO)

Ara Metjian, MD
Program Director
Paul Coppo, MD, PhD Marshall Mazepa, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: January 26, 2022 Expired: January 25, 2023

Free video from Clinical Care Options (CCO) featuring expert discussion of use of asparaginase-based treatments in young and older adults with acute lymphoblastic leukemia

Wendy Stock, MD
Program Director
Emily Curran, MD Dan Douer, MD person default Scott Howard, MD, MSc person default Stephen P. Hunger, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 24, 2022 Expired: January 23, 2023

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings